Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)
A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Paroxysmal Nocturnal Hemoglobinuria (PNH), this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 25 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
25 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 20 earlier versions
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2023 — May 2024 [monthly]
Completed PHASE3
-
May 2023 — Dec 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Oct 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .